Navigation Links
UB's bioblower closer to protecting soldiers from biological attack
Date:2/28/2008

BUFFALO, N.Y. -- A powerful air sterilization technology developed at the University at Buffalo has killed every biological agent with which it has been challenged, including airborne spores, viruses and bacteria in independent tests conducted for the U.S. Department of Defense.

A prototype produced by Buffalo BioBlower Technologies LLC, a UB spin-off company, destroyed biological agents to a level of better than one part per million in an independent evaluation conducted over a period of four weeks by the Research Triangle Institute for the U.S. Department of Defense Joint Program for Chemical and Biological Defense Collective Protection.

In a related development, UB recently received a Notice of Allowance, indicating that a U.S. patent will issue soon covering the BioBlower technology.

Everything from hospitals, first-responder units and postal facilities to government buildings and mass-transit systems could benefit enormously from the security and peace of mind generated by this device, said Rep. Louise M. Slaughter. Once again, our region is serving as a leader in technological development, and it is this labor and innovation that are benefiting people both locally and throughout our country.

The positive outcomes in the independent evaluation indicate that BioBlower could, in the near future, be protecting soldiers from biological attack, according to James F. Garvey, Ph.D., professor in the Department of Chemistry in the UB College of Arts and Sciences and co-founder and chief technical officer of Buffalo BioBlower Technologies, with John Lordi, Ph.D., chief executive officer.

Lordi is a research professor in the Department of Mechanical and Aerospace Engineering in the UB School of Engineering and Applied Sciences. James D. Felske, Ph.D., and Joseph C. Mollendorf, Ph.D., professors in the same department, are co-inventors with Garvey and Lordi.

This independent third-party validation of our technology was so exceptionally com
'/>"/>

Contact: Ellen Goldbaum
goldbaum@buffalo.edu
716-645-5000 x1415
University at Buffalo
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. UGA researchers 1 step closer to elusive cancer vaccine
2. Research Gets Closer to Origin of Parkinsons Disease
3. Study Gets Closer to Origins of Leukemia
4. Bug guts map brings scientists closer to understanding different bugs role in the body
5. APHA Urges President Bush Not To Veto CHIP; Were Only One Signature Away from Protecting the Health of Our Children
6. Medical identity theft: the importance of protecting your health records
7. National Patient Advocate Foundation Hails Senator Rockefeller for Introducing Bill Protecting Patient Access to Health Coverage
8. Doctors, economist, write prescription for protecting people from themselves
9. Congressman Tom Reynolds Awarded for Protecting Medicare Choices
10. OHSU research suggests new strategy for protecting aging Americans against infectious disease
11. An emerging candidate for protecting patients from liver injury after abdomen surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4WaferGen Adds Robert Coradini Former President of J 26amp 3BJ New Ventures to Board of Directors 60222 1WaferGen Adds Robert Coradini Former President of J 26amp 3BJ New Ventures to Board of Directors 60222 2WaferGen Adds Robert Coradini Former President of J 26amp 3BJ New Ventures to Board of Directors 60222 3Red Cross Offers the Trick to Safety this Halloween 60220 1Red Cross Offers the Trick to Safety this Halloween 60220 2Connectyx Announces the MedFlash Personal Health Manager 60218 1Connectyx Announces the MedFlash Personal Health Manager 60218 2Connectyx Announces the MedFlash Personal Health Manager 60218 3